NICE Accepts Fewer Side Effects In Recommending Sanofi-Aventis's Multaq
This article was originally published in The Pink Sheet Daily
Executive Summary
Second draft appraisal of Multaq recommends use in atrial fibrillation, even though the drug is less effective than other anti-arrhythmics